The Germantown, Maryland-based company launched Eversense 365, its implantable CGM in 2024. Eversense 365 rests under the skin for the duration of a year. Users can change the device’s external, silicone-based adhesive daily with almost no skin reactions.
Eversense 365 is also an integrated CGM (iCGM) system, meaning it can work with compatible medical devices. Those include insulin pumps as part of automated insulin delivery systems. Senseonics launched its system with the Sequel Med Tech twiist pump earlier this year.
The journey to get there has been an intriguing one, and the technology behind Eversense 365 is paving new roads in diabetes management. On top of the innovation
Senseonics Vice President of Product Development, Hari Sree, will take part in an upcoming Medical Design & Outsourcing webinar on April 9, during which he will explain the innovation behind Eversense 365 and the future technology coming at Senseonics.
In this webinar, you will learn:
- The evolution of the Eversense CGM System.
- Fundamental principles of operation and technology of the commercially available Eversense 365 System.
- Senseonics’ future pipeline and technology.
Join Hari Sree, Vice President of Product Development at Senseonics, as he discusses the evolution of the Eversense 365 CGM system, its technology, and the fundamental principles behind the sensor, before diving into the company’s future pipeline and the technology behind next-generation continuous glucose monitors. Register for free here for the webinar taking place on Thursday, April 9, at 2 p.m. ET.
